ACOG 10% Owner Opaleye Management Inc. Buys $143K of Stock
Key Points
- Opaleye Management's recent purchase of 17,117 shares raises its total ownership in Alpha Cognition to 3,277,011 shares.
- The stock closed at $8.31 on October 22, 2026, and recently traded around $8.30, which is about equal to its closing price.
- Analysts have a consensus price target of $18.00 for Alpha Cognition, significantly above the recent trading levels.
Since the trade, $ACOG is up 0.4% to date (from the $8.31 close on Oct 22, 2026).
Get Alpha Cognition Common Stock text alerts
We text you when insiders, Congress, analysts or big funds move on $ACOG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alpha Cognition Inc. Common Stock alert may contain errors. Disclosures
On October 22, 2026, Opaleye Management Inc. bought 17,117 shares of Alpha Cognition Inc. (ACOG) for about $142,526. This purchase increases Opaleye's stake to 3,277,011 shares. The information comes from a Form 4 filing with the SEC.
Opaleye Management, a 10% owner of Alpha Cognition, made this purchase at an average price of $8.33 per share. This move marks a 0.53% increase in their ownership position. The stock closed at $8.31 on the same day, reflecting a stable trading environment around this price.
ACOG
Alpha Cognition Inc. Common Stock
Opaleye Management Inc. vs. the S&P 500
Hypothetical returns from Opaleye Management Inc.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Alpha Cognition
Opaleye Management also reported a sizable position in Alpha Cognition prior to this purchase. As of June 30, 2026, it held 2,895,467 shares valued at about $24.0 million, growing its holdings by 333,560 shares, a 13% increase. Other funds, such as Solas Capital Management and AWM Investment Company, maintained their positions without changes.
Alpha Cognition Inc. Common Stock Stock Down 0.1%
Alpha Cognition shares are currently trading slightly below their 50-day moving average by about 7.2%. The stock is also about 18.1% below its 52-week high of $10.14, while it is significantly above its 52-week low of $4.50, indicating a recovery in its price over the past year.
Recent Earnings
In its latest earnings report, Alpha Cognition showed trailing twelve-month revenue of $15.3 million, a notable 267.6% increase year-over-year. However, the company reported a negative net margin of -137.7%, indicating ongoing challenges in profitability. The next earnings report is scheduled for November 12, 2026.
Insider Buying and Selling at Alpha Cognition Inc. Common Stock
Recently, Opaleye Management has been active in buying shares of Alpha Cognition. On October 15, 2026, it purchased 22,657 shares at an average price of $8.43, followed by another purchase of 14,283 shares on October 16 at $8.23. These transactions reflect a strategic increase in their holdings.
Analysts Set New Price Targets
On July 10, 2026, Raymond James initiated coverage of Alpha Cognition with an Outperform rating and a price target of $20.00. HC Wainwright & Co. maintained a Buy rating on August 17, 2026, also with a target of $20.00, while B. Riley Securities initiated coverage with a Buy rating and a target of $21.00 on August 20, 2026. The consensus price target stands at $18.00, indicating a strong outlook from analysts.
About Alpha Cognition
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's. The company's leading product is ZUNVEYL, an oral tablet formulation aimed at improving patient outcomes. This recent insider buying activity highlights confidence in the company's future prospects.
Bottom Line
Investors should keep an eye on Alpha Cognition's upcoming earnings report on November 12, 2026, and any further insider activities that may indicate management's confidence in the company's direction. Opaleye Management's ongoing purchases suggest a bullish outlook as they continue to build their stake in the company.
Related Filing Alerts
Source: Opaleye Management Inc.'s Form 4 filing on $ACOG (Oct 22, 2026). Written by software, not financial advice. How we make alerts